Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$3.70M$3.70M+12.6% vs Q2 2021 Net Income-$10.34M-$10.34MN/M vs Q2 2021 EPS Diluted-$0.14-$0.14N/M vs Q2 2021 Operating Income-$12,330,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$16,207,000N/M Margins · derivedOperating margin-333.4%+176.8 pt vs Q2 2021
Net margin-279.6%+192.2 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end